Cargando…
Multiresistant bacteria and current therapy - the economical side of the story
Severe infections with multiresistant bacteria (MRB) are a medical challenge and a financial burden for hospitals. The adequate antibiotic therapy is a key issue in multiresistant bacteria management. Several major cost drivers have been identified. Remarkably drug acquisition costs are not necessar...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352106/ https://www.ncbi.nlm.nih.gov/pubmed/21163732 http://dx.doi.org/10.1186/2047-783X-15-12-571 |